LTC1673106I2 - ŽPV 45 L1 optimizuota ekspresija mielėse - Google Patents

ŽPV 45 L1 optimizuota ekspresija mielėse

Info

Publication number
LTC1673106I2
LTC1673106I2 LTPA2015049C LTPA2015049C LTC1673106I2 LT C1673106 I2 LTC1673106 I2 LT C1673106I2 LT PA2015049 C LTPA2015049 C LT PA2015049C LT PA2015049 C LTPA2015049 C LT PA2015049C LT C1673106 I2 LTC1673106 I2 LT C1673106I2
Authority
LT
Lithuania
Prior art keywords
hpv
yeast
optimized expression
optimized
expression
Prior art date
Application number
LTPA2015049C
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of LTC1673106I2 publication Critical patent/LTC1673106I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
LTPA2015049C 2003-09-29 2015-12-08 ŽPV 45 L1 optimizuota ekspresija mielėse LTC1673106I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Publications (1)

Publication Number Publication Date
LTC1673106I2 true LTC1673106I2 (lt) 2017-05-10

Family

ID=34421558

Family Applications (2)

Application Number Title Priority Date Filing Date
LTPA2015049C LTC1673106I2 (lt) 2003-09-29 2015-12-08 ŽPV 45 L1 optimizuota ekspresija mielėse
LTPA2015049D LTPA2015049I1 (lt) 2003-09-29 2015-12-08 Žpv 45 l1 optimizuota ekspresija mielėse

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2015049D LTPA2015049I1 (lt) 2003-09-29 2015-12-08 Žpv 45 l1 optimizuota ekspresija mielėse

Country Status (33)

Country Link
US (2) US7250170B2 (lt)
EP (1) EP1673106B1 (lt)
JP (4) JP5451960B2 (lt)
KR (1) KR101165278B1 (lt)
CN (1) CN1859923B (lt)
AR (2) AR045804A1 (lt)
AT (1) ATE435029T1 (lt)
AU (1) AU2004277934B2 (lt)
BE (1) BE2015C072I2 (lt)
BR (1) BRPI0414845B8 (lt)
CA (1) CA2539168C (lt)
CY (2) CY1110525T1 (lt)
DE (1) DE602004021828D1 (lt)
DK (1) DK1673106T3 (lt)
ES (1) ES2327530T3 (lt)
FR (1) FR15C0083I2 (lt)
HU (1) HUS1500063I1 (lt)
IL (1) IL174458A (lt)
IS (1) IS2694B (lt)
LT (2) LTC1673106I2 (lt)
LU (1) LU92902I2 (lt)
MX (1) MXPA06003457A (lt)
MY (1) MY140664A (lt)
NL (1) NL300776I1 (lt)
NO (3) NO339932B1 (lt)
NZ (1) NZ545834A (lt)
PL (1) PL1673106T3 (lt)
PT (1) PT1673106E (lt)
RU (1) RU2360001C2 (lt)
SI (1) SI1673106T1 (lt)
TW (1) TWI350853B (lt)
WO (1) WO2005032586A1 (lt)
ZA (1) ZA200601961B (lt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
CA2560487C (en) * 2004-03-24 2013-01-29 Merck & Co., Inc. Optimized expression of hpv 52 l1 in yeast
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
KR100904844B1 (ko) * 2006-08-28 2009-06-25 성균관대학교산학협력단 인유두종 바이러스（ｈｐｖ）유전자를 포함하는자궁경부암의 치료 또는 예방용 ｄｎａ 백신
WO2008112125A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
EP2223933B1 (en) * 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein l1 of human papilloma viruses
US9566323B2 (en) 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
CA2839427C (en) * 2011-06-15 2016-09-27 Chung-Ang University Industry-Academic Cooperation Foundation Method for enhancing the production yield of human papillomavirus l1 protein
EP2723371B1 (en) 2011-06-24 2019-10-23 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN104120088B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104164447B (zh) * 2013-05-17 2019-08-13 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN104513826B (zh) * 2013-09-29 2020-10-20 上海泽润生物科技有限公司 人乳头瘤病毒基因,及载体,菌株,表达方法
WO2015057541A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
AU2015313756A1 (en) * 2014-09-11 2017-03-09 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
MX2022009964A (es) 2020-02-14 2022-09-19 Merck Sharp & Dohme Llc Vacuna contra hpv.
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
TW202313658A (zh) 2021-08-06 2023-04-01 美商默沙東有限責任公司 Hpv疫苗
MX2024002144A (es) 2021-08-19 2024-04-23 Merck Sharp & Dohme Llc Nueva nanoparticula lipidica termostable y metodos de uso de la misma.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031532A1 (en) * 1994-05-16 1995-11-23 Merck & Co., Inc. Papillomavirus vaccines
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
ATE342916T1 (de) 1997-02-07 2006-11-15 Merck & Co Inc Synthetische hiv gag gene
AU734761B2 (en) * 1997-05-27 2001-06-21 Hanil Synthetic Fiber Co., Ltd. Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae
JP4434479B2 (ja) 1997-07-09 2010-03-17 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
DE69933875T2 (de) * 1998-08-14 2007-05-31 Merck & Co., Inc. Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
DE69924007T2 (de) * 1998-12-23 2006-04-06 Merck & Co., Inc. Neutralsierungs-assay, das humane papillomavirus-ähnliche partikel verwendet
CA2381991A1 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic human papillomavirus genes
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
DE60124918T2 (de) 2000-07-21 2007-08-02 Glaxo Group Ltd., Greenford Kodon-optimierte papillomavirussequenzen
WO2003068993A1 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
BRPI0408639B8 (pt) 2003-03-24 2021-05-25 Merck Sharp & Dohme molécula de ácido nucleico, vetor, célula hospedeira de levedura e método para produzir partículas semelhantes a vírus de hpv31

Also Published As

Publication number Publication date
PT1673106E (pt) 2009-09-22
CY2015050I2 (el) 2016-06-22
SI1673106T1 (sl) 2009-12-31
IL174458A (en) 2014-06-30
CA2539168C (en) 2011-05-31
BRPI0414845B8 (pt) 2021-06-15
LU92902I2 (fr) 2016-03-08
EP1673106A1 (en) 2006-06-28
AU2004277934A1 (en) 2005-04-14
ATE435029T1 (de) 2009-07-15
US20080138361A1 (en) 2008-06-12
BRPI0414845B1 (pt) 2020-10-13
IS2694B (is) 2010-11-15
LTPA2015049I1 (lt) 2016-01-11
MY140664A (en) 2010-01-15
TW200521233A (en) 2005-07-01
MXPA06003457A (es) 2006-06-05
CN1859923B (zh) 2012-09-05
KR101165278B1 (ko) 2012-07-23
RU2006114701A (ru) 2007-11-10
JP2011152137A (ja) 2011-08-11
AU2004277934B2 (en) 2009-09-17
NO20061876L (no) 2006-04-28
JP2016136947A (ja) 2016-08-04
DE602004021828D1 (de) 2009-08-13
CY2015050I1 (el) 2016-06-22
IL174458A0 (en) 2006-08-01
IS8362A (is) 2006-03-20
EP1673106B1 (en) 2009-07-01
NL300776I2 (lt) 2015-12-29
WO2005032586A1 (en) 2005-04-14
NO2022051I1 (no) 2022-11-30
AR077396A2 (es) 2011-08-24
KR20070029628A (ko) 2007-03-14
ZA200601961B (en) 2007-05-30
JP5451960B2 (ja) 2014-03-26
PL1673106T3 (pl) 2009-12-31
ES2327530T3 (es) 2009-10-30
NO339932B1 (no) 2017-02-20
JP2014221052A (ja) 2014-11-27
US20060240040A1 (en) 2006-10-26
AR045804A1 (es) 2005-11-16
CA2539168A1 (en) 2005-04-14
HUS1500063I1 (hu) 2016-02-29
NO2017012I1 (no) 2017-04-05
CY1110525T1 (el) 2015-04-29
RU2360001C2 (ru) 2009-06-27
FR15C0083I1 (fr) 2016-08-01
BRPI0414845A (pt) 2006-11-21
FR15C0083I2 (fr) 2016-11-25
CN1859923A (zh) 2006-11-08
DK1673106T3 (da) 2009-11-09
BE2015C072I2 (lt) 2023-12-14
US7482015B2 (en) 2009-01-27
US7250170B2 (en) 2007-07-31
NZ545834A (en) 2009-02-28
JP2007507207A (ja) 2007-03-29
NL300776I1 (lt) 2015-12-29
TWI350853B (en) 2011-10-21

Similar Documents

Publication Publication Date Title
LTC1673106I2 (lt) ŽPV 45 L1 optimizuota ekspresija mielėse
CY2015051I2 (el) Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα
LTPA2015050I1 (lt) Optimizuota hpv 52 l1 raiška mielėse
DE60317699D1 (de) Fermentationsverfahren und -zusammensetzungen
NO20024304D0 (no) Anordning ved stillbar stol
DK1499197T3 (da) Törgærsammensætning
SE0102342D0 (sv) Modified yeast
ITMO20040195A1 (it) 'kit per la raccolta e la collezione di figurine'.
ITFI20030193A1 (it) Lievito per vinificazione.